"uuid:ID","id","rationale","instanceType","versionIdentifier"
"6b2139e0-65c3-4993-9467-77d15dddbed2","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","2"
